Company,Total_Links,Text_Length_Characters,Extraction_Date,Status
BIOCON,2,656,2025-08-21 21:11:20,Completed

EXTRACTED_LINKS
Link_Number,URL
Link_1,"https://ehealth.eletsonline.com/2025/05/biocon-biologics-achieves-major-u-s-market-access-for-yesintek-strengthening-indias-global-biopharma-footprint/#:~:text=The%20biosimilar%20will%20be%20covered,formularies%20effective%20July%201%2C%202025."
Link_2,https://ehealth.eletsonline.com/2025/05/biocon-biologics-achieves-major-u-s-market-access-for-yesintek-strengthening-indias-global-biopharma-footprint/

EXTRACTED_TEXT_CONTENT
Content_Type,Content
Complete_Text,"This biosimilar is now covered underUnitedHealthcare's commercial plans, which began onMay 1, 2025.

Further expansion of coverage to Managed Medicaid and Medicare plans is planned for later in 2025.

Other major Pharmacy Benefit Managers likeCVS Health and Optum Rxhave also added Yesintek™ to their formularies, effective July 1, 2025.

As of May 1, 2025, there was news regarding Biocon's market access for its biosimilar, Yesintek™ (ustekinumab-kfce), in the United States .

This expanded market access strengthens Biocon's presence in the US biosimilars market and is considered a significant development for the company's global biopharma footprint."
